July 4, 2022

SELLAS Life Sciences announces settlement of counterclaims against JGB (Cayman) Newton, Ltd. for $6.6 million payment by JGB

Pin It

Follows Dismissal by Court of All Claims Against SELLAS  Debenture and All Security Interests Held by JGB Terminated NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, […]